Business
Femasys Announces Partnership with Refuah Health Center to Expand First-Line Access to FemaSeed® in Community-Based Care
Partnership enables broader adoption of FemaSeed through a trusted community health provider serving a large, engaged patient populationATLANTA , Jan. 13, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced today a partnership with Refuah Health Center to offer FemaSeed as a first step in the infertility treatment process. The partnership is
About this update from Femasys Inc.
[{"type":"image","alt":"Femasys Inc.","displaySize":"","headline":null,"caption":"Femasys Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":122,"url":"https://media.zenfs.com/en/globenewswire.com/301b83514d43baad2f5211eaa290a825"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/GL8WCCgrHOHP9r8Vdi7XpQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE3MTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/301b83514d43baad2f5211eaa290a825","width":300,"height":122}},"lazy":false},{"type":"text","content":"Partnership enables broader adoption of FemaSeed through a trusted community health provider serving a large, engaged patient population","length":136,"tagName":"p"},{"type":"text","content":"ATLANTA , Jan. 13, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced today a partnership with Refuah Health Center to offer FemaSeed as a first step in the infertility treatment process. The partnership is expected to strengthen Femasys’ commercial footprint in community-based fertility care by expanding patient access and supporting increased utilization of FemaSeed as a first-line approach.","length":553,"tagName":"p"},{"type":"text","content":"“This partnership is an important step forward in expanding the commercial availability of FemaSeed within community-based fertility care,” said Kathy Lee-Sepsick, Chief Executive Officer of Femasys. “With Refuah’s trusted care model and strong patient engagement, we expect to accelerate adoption of FemaSeed by providing a more accessible, cost-effective, and patient-centered starting point for fertility treatment.”","length":419,"tagName":"p"},{"type":"text","content":"“At Refuah, our focus is on providing patients with practical, evidence-based options that can streamline the fertility journey,” said Dr. Angela Silber, M.D., OB/GYN, at Refuah Health Center. “FemaSeed offers an accessible, patient-centered approach that may help many individuals begin care sooner and with less complexity, and we are pleased to make it available as an early step in treatment.”","length":397,"tagName":"p"},{"type":"text","content":"About FemaSeedFemaSeed® is a next-generation artificial insemination solution that enhances fertilization by precisely delive...